 BEIJING--BUSINESS WIRE--Sinovac Biotech Ltd. Sinovac or the Company NASDAQ: SVA, a leading provider of biopharmaceutical products in China, today announced that the third production line of CoronaVac, its COVID-19 vaccine, was completed and put into commercial production. Including this new production line, Sinovacs annual capacity of CoronaVac has reached 2 billion doses. At this time, over 200 million doses of CoronaVac have been delivered to over 20 countries, including China. I 